Physician profile
Adel Youssef
NPI 1891788477
$8,519.28
in general payments reported to CMS, 2019-2025
39 companies · $710 in 2025
The $710 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $1,611 · 2021: $2,295 · 2022: $1,402 · 2023: $572 · 2024: $554 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.90 |
| Education | $114.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,083.30 | 2019-2025 | Mavyret, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,610.51 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $1,335.90 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $686.74 | 2019-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $307.12 | 2019-2024 | |
| Ardelyx, INC. | $266.86 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $253.20 | 2019-2025 | Injectafer |
| Intercept Pharmaceuticals, INC. | $240.80 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $211.37 | 2019-2021 | |
| Redhill Biopharma INC. | $178.22 | 2020-2022 | |
| Genzyme Corporation | $166.88 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $135.75 | 2021-2023 | |
| Pfizer INC. | $128.86 | 2019-2024 | |
| Qol Medical, LLC | $126.41 | 2020-2025 | Sucraid, Sucraid |
| Ucb, INC. | $97.77 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $79.51 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $67.32 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $47.26 | 2025 | Voquezna |
| Medtronic, INC. | $47.00 | 2023-2025 | Altaviva, Gi Genius, Interstim |
| Lilly USA, LLC | $44.78 | 2024-2025 | Omvoh |
| Stryker Corporation | $42.58 | 2025 | Neptune, Pedi-Pom |
| Organon LLC | $39.91 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $34.96 | 2024-2025 | Bylvay |
| Aimmune Therapeutics, INC. | $30.74 | 2024-2025 | Zenpep |
| Shionogi INC | $26.88 | 2019-2020 | |
| Madrigal Pharmaceuticals | $25.50 | 2025 | Rezdiffra |
| Novo Nordisk INC | $24.21 | 2025 | Wegovy |
| Echosens North America, INC. | $23.00 | 2021 | |
| Axonics, INC. | $20.01 | 2021 | |
| Celltrion USA INC. | $18.07 | 2024 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $14.30 | 2024 | Dupixent |
| Fresenius Kabi USA, LLC | $14.20 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $14.13 | 2023 | Terlivaz |
| Csl Behring | $13.57 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.31 | 2023 | Cyltezo |
| Celgene Corporation | $13.11 | 2022 | |
| Conmed Corporation | $12.20 | 2019 | |
| Concordia Pharmaceuticals INC. | $11.87 | 2019 | |
| Allergan, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.